2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 5.572

Change

0.00 (0.00)%

Market Cap

USD 0.52B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.04 (-0.08%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.05%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.10%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.09%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.05 (-0.21%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

+0.58 (+0.38%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+0.64 (+0.46%)

USD 102.14B
JARI:XETRA Amundi Index Solutions - Amund..

+0.15 (+0.34%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.04 (-0.07%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.32 (+0.26%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.30% 14% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.30% 14% F 20% F
Trailing 12 Months  
Capital Gain 2.14% 28% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.14% 28% F 34% F
Trailing 5 Years  
Capital Gain 28.98% 53% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.98% 52% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 6.65% 64% D 62% D
Dividend Return 6.65% 62% D 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.64% 41% F 52% F
Risk Adjusted Return 45.40% 57% F 60% D-
Market Capitalization 0.52B 69% C- 61% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.